https://scholars.lib.ntu.edu.tw/handle/123456789/538694
標題: | Stem cell transplantation for T-cell lymphomas in Taiwan | 作者: | Hsu Y.-T. Tsai H.-J. Chang J.S. Li S.-S. JIH-LUH TANG Yeh S.-P. Hwang W.-L. Liu J.-H. Tan T.-D. Wang P.-N. Hsiao H.-H. Chen T.-Y. |
公開日期: | 2018 | 出版社: | Nature Publishing Group | 卷: | 53 | 期: | 8 | 起(迄)頁: | 993-1000 | 來源出版物: | Bone Marrow Transplantation | 摘要: | T-cell lymphomas are generally aggressive malignancies with poor prognosis. There are no standard treatment guidelines for T-cell lymphomas, and the timing of stem cell transplantation (SCT) is not well known. In this study, we investigated the outcomes of Taiwanese patients with T-cell lymphomas after SCT. We retrospectively analyzed 131 patients with T-cell lymphomas receiving SCT (autologous: 90, allogeneic: 41) from 2009 to 2014. More autologous SCT recipients were ALCL or in complete remission, and more allogeneic recipients had advanced disease. 56 patients who were sensitive to chemotherapy underwent SCT as upfront setting. The 2-year PFS and OS rates were 67.0 and 64.5%, respectively. Regarding disease status before transplantation, patients with CR1 had the best outcomes. Among different subtypes, patients with natural killer/T-cell lymphomas showed the worst outcomes, with 2-year OS rate of 23.5%. The OS rates for the other three major subtypes were as follows: 72.9% for ALCL; 75.0% for AITL; and 51.4% for PTCL-NOS. For more rare subtypes, such as ATLL and SPTCL, data from our study show that SCT can be beneficial. We concluded that upfront autologous SCT is feasible and effective for patients with low PIT, and disease status at transplant is the strong predictor of outcome. ? 2018, Macmillan Publishers Limited, part of Springer Nature. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041922984&doi=10.1038%2fs41409-018-0116-6&partnerID=40&md5=8a0c71dcc27ae18ec16b2e2ac0a823e4 https://scholars.lib.ntu.edu.tw/handle/123456789/538694 |
ISSN: | 0268-3369 | DOI: | 10.1038/s41409-018-0116-6 | SDG/關鍵字: | busulfan; cyclophosphamide; fludarabine; melphalan; allogeneic stem cell transplantation; anaplastic large cell lymphoma; angioimmunoblastic t cell lymphoma; Article; autologous stem cell transplantation; cancer prognosis; cancer regression; cancer staging; controlled study; drug sensitivity; feasibility study; graft recipient; human; major clinical study; NK T cell lymphoma; nonmyeloablative conditioning; outcome assessment; overall survival; peripheral T cell lymphoma; priority journal; progression free survival; reduced intensity conditioning; retrospective study; stem cell transplantation; subcutaneous t cell lymphoma; survival time; T cell lymphoma; Taiwan; Taiwanese; treatment response; whole body radiation; adult; allotransplantation; female; male; middle aged; pathology; procedures; stem cell transplantation; T cell lymphoma; young adult; Adult; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Taiwan; Transplantation, Homologous; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。